Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case

Moderna stock is rated Sell amid FDA setbacks for mRNA-1010, commoditized COVID/RSV sales, and cash burn. Read the analysis ...
Blockonomi

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.

Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ...
Just The News

Moderna threatens American jobs after FDA snubs mRNA flu shot, trial looked 'scientifically lax'

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...